Clinical Trial Update: Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A

View source ↗

Summary

Completed post-marketing surveillance evaluating safety and efficacy of Xyntha in Hemophilia A; results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Xyntha (recombinant coagulation factor VIII)

Snippet

Sponsor: Pfizer | Conditions: Hemophilia A | Status: COMPLETED | Results posted: 2015-08-17